Current Report Filing (8-k)
September 06 2017 - 04:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 30, 2017
Versartis, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36361
|
|
26-4106690
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
4200 Bohannon Drive, Suite 250
Menlo Park, California
|
|
94025
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650)
963-8580
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of
this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Chief Development Officer; Appointment of Chief
Medical Officer
On September 5, 2017, Versartis, Inc. (the
Company
) announced the appointment of Dr. Robert Gut, M.D.,
Ph.D., to the position of Chief Medical Officer. On August 30, 2017, Dr. Colin Hislop, M.D., relinquished his duties as Chief Medical Officer, effective September 5, 2017, and will continue leading the Companys development
activities as Chief Development Officer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: September 6, 2017
|
|
|
|
Versartis, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Joshua T. Brumm
|
|
|
|
|
|
|
Joshua T. Brumm
|
|
|
|
|
|
|
Chief Financial Officer and Chief Operating Officer
|
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Feb 2024 to Mar 2024
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Mar 2023 to Mar 2024